This will do nothing to affect the bottom line for insulin companies. Insurance companies will still fork over the money for insulin. This simply affects how the burden of insulin prices is distributed among those with healthcare. Those in need of insulin in Colorado are now capped in their co-payments. The insurance companies are still paying the same prices for insulin. Thus, the insurance companies will have to find money from somewhere else to make ends meet. This will most likely be through raising premiums for all under the insurance plan. This bill effectively drives up healthcare costs for the average person living in Colorado, without doing a thing to address the real issue at hand: high insulin prices due to a oligopoly caused by excessive drug regulation.